581
Participants
Start Date
October 16, 2013
Primary Completion Date
January 18, 2018
Study Completion Date
November 16, 2018
Trabectedin
1.1 mg/m\^2 administered intravenously over approximately 3 hours on Day 1 of each 21-day treatment cycle.
DOXIL
30 mg/m\^2 administered intravenously over approximately 90 minutes on Day 1 of each 21-day treatment cycle.
Dexamethasone
20 mg administered intravenously on Day 1 of each 21-day treatment cycle approximately 30 minutes prior to study drug infusion.
DOXIL
50 mg/m\^2 administered intravenously over approximately 90 minutes on Day 1 of each 28-day treatment cycle.
Birmingham
Phoenix
Scottsdale
Sedona
Tucson
Hot Springs
Greenbrae
La Jolla
Los Angeles
Orange
Sacramento
Englewood
New Britain
New Haven
Stamford
Fort Myers
Jacksonville
Miami
Sarasota
St. Petersburg
Tampa
Atlanta
Savannah
Chicago
Park Ridge
Indianapolis
Louisville
Covington
New Orleans
Scarborough
Worcester
Detroit
Lansing
Duluth
Edina
Columbia
Kansas City
Hackensack
Morristown
New Brunswick
Summit
Brightwaters
Hawthorne
New York
Pinehurst
Akron
Cincinnati
Cleveland
Columbus
Tulsa
Portland
Abington
Pittsburgh
Providence
Charleston
Greenville
Nashville
Austin
Bedford
Dallas
Fort Worth
Houston
San Antonio
The Woodlands
Webster
Salt Lake City
Annandale
Newport News
Roanoke
Spokane
Vancouver
Green Bay
Madison
Milwaukee
Wauwatosa
Adelaide
Ballarat
Brisbane
Gosford
Parkville
Subiaco
Toorak Gardens
Townsville
Wodonga
Woodville
Guangzhou
Jinan
Shanghai
Shenyang
Beersheba
Haifa
Holon
Jerusalem
Kfar Saba
Petah Tikva
Ramat Gan
Rehovot
Tel Aviv
Ẕerifin
Auckland
Wellington
Bydgoszcz
Gdansk
Lublin
Poznan
Warsaw
Arkhangelsk
Chelyabinsk
Ivanovo
Kirov
Krasnodar
Moscow
Nal'chik
Nizhny Novgorod
Omsk
Orenburg
Pyatigorsk
Ryazan
Saint Petersburg
Sochi
Ufa
Yaroslavl
Cape Town
Durban
eManzimtoti
Johannesburg
Port Elizabeth
Pretoria
Bern
Zurich
Bebington
Glasgow
Guildford
London
Maidstone
Manchester
Plymouth
Swansea
Collaborators (1)
PharmaMar
INDUSTRY
Janssen Research & Development, LLC
INDUSTRY